纳武利尤单抗联合或不联合伊匹木单抗治疗复发或转移性宫颈癌(CheckMate 358):一项1-2期、开放标签、多队列试验
CheckMate 358研究复发或转移性宫颈癌队列长期结果显示,纳武利尤单抗单药客观缓解率为26%(5/19,95%CI 9-51),NIVO3+IPI1组为31%(14/45,95%CI 18-47),随机NIVO1+IPI3组为40%(18/45,95%CI 26-56),汇总NIVO1+IPI3组为38%(43/112,95%CI 29-48)。NIVO1+IPI3组发生1例治疗相关死亡(免疫介导性结肠炎)。作者认为纳武利尤单抗单药及联合伊匹木单抗在该人群中显示前景,需未来随机对照试验证实治疗获益。
要点
- 纳武利尤单抗单药客观缓解率26%(5/19,95%CI 9-51)。
- NIVO3+IPI1组客观缓解率31%(14/45,95%CI 18-47)。
- 随机NIVO1+IPI3组客观缓解率40%(18/45,95%CI 26-56);汇总NIVO1+IPI3组38%(43/112,95%CI 29-48)。
核心结论
- 纳武利尤单抗单药及纳武利尤单抗联合伊匹木单抗在CheckMate 358研究中作为复发或转移性宫颈癌的潜在治疗选择显示前景。
- 作者认为需要未来随机对照试验评估纳武利尤单抗联合伊匹木单抗或其他双免疫方案以确认该人群的治疗获益。
研究设计与样本
- CheckMate 358为1-2期、开放标签、多队列试验,宫颈癌队列自十个国家30家医院和癌症中心入组患者。
- 入组18岁及以上女性,组织学确诊宫颈鳞状细胞癌伴复发或转移性疾病,ECOG体能状态0或1,既往系统治疗不超过两种。
- 患者分入纳武利尤单抗240 mg每2周组、随机组(NIVO3+IPI1或NIVO1+IPI3)或NIVO1+IPI3扩展组;随机组按1:1随机分配。
- NIVO3+IPI1为纳武利尤单抗3 mg/kg每2周联合伊匹木单抗1 mg/kg每6周;NIVO1+IPI3为纳武利尤单抗1 mg/kg每3周联合伊匹木单抗3 mg/kg每3周共4周期,之后纳武利尤单抗240 mg每2周;所有剂量均静脉给药。
- 治疗持续至疾病进展、不可接受毒性或撤回知情同意,或最长24个月;主要终点为研究者评估的客观缓解率。
主要发现
- 2015年10月至2020年3月,宫颈癌队列入组193例患者,其中176例接受治疗;19例接受纳武利尤单抗单药,45例接受NIVO3+IPI1,112例接受NIVO1+IPI3(随机组45例,扩展组67例)。
- 中位随访时间:纳武利尤单抗组19.9个月(IQR 8.2-44.8),NIVO3+IPI1组12.6个月(IQR 7.8-37.1),汇总NIVO1+IPI3组16.7个月(IQR 7.2-27.5)。
- 客观缓解率:纳武利尤单抗组26%(95%CI 9-51;5/19例),NIVO3+IPI1组31%(95%CI 18-47;14/45例),随机NIVO1+IPI3组40%(95%CI 26-56;18/45例),汇总NIVO1+IPI3组38%(95%CI 29-48;43/112例)。
- 最常见的3-4级治疗相关不良事件:纳武利尤单抗组为腹泻、肝细胞溶解、低钠血症、肺炎和晕厥(各1例[5%]);NIVO3+IPI1组为腹泻、γ-谷氨酰转移酶升高、脂肪酶升高和呕吐(各2例[4%]);汇总NIVO1+IPI3组为脂肪酶升高(9例[8%])和贫血(7例[6%])。
- 严重治疗相关不良事件:纳武利尤单抗组3例(16%),NIVO3+IPI1组12例(27%),汇总NIVO1+IPI3组47例(42%);NIVO1+IPI3组发生1例治疗相关死亡(免疫介导性结肠炎)。
临床怎么用
- 作者认为纳武利尤单抗单药和纳武利尤单抗联合伊匹木单抗在复发或转移性宫颈癌中显示前景,为潜在治疗选择。
- 作者建议未来开展纳武利尤单抗联合伊匹木单抗或其他双免疫方案的随机对照试验以确认治疗获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the combination of nivolumab plus ipilimumab showed promising clinical activity. Here, we report long-term outcomes from this cohort. METHODS: CheckMate 358 was a phase 1-2, open-label, multicohort trial. The metastatic cervical cancer cohort enrolled patients from 30 hospitals and cancer centres across ten countries. Female patients aged 18 years or older with a histologically confirmed diagnosis of squamous cell carcinoma of the cervix with recurrent or metastatic disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and up to two previous systemic therapies were enrolled into the nivolumab 240 mg every 2 weeks group, the randomised groups (nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks [NIVO3 plus IPI1] or nivolumab 1 mg/kg every 3 weeks plus ipilimumab 3 mg/kg every 3 weeks for four cycles then nivolumab 240 mg every 2 weeks [NIVO1 plus IPI3]), or the NIVO1 plus IPI3 expansion group. All doses were given intravenously. Patients were randomly assigned (1:1) to NIVO3 plus IPI1 or NIVO1 plus IPI3 via an interactive voice response system. Treatment continued until disease progression, unacceptable toxicity, or consent withdrawal, or for up to 24 months. The primary endpoint was investigator-assessed objective response rate. Anti-tumour activity and safety were analysed in all treated patients. This study is registered with ClinicalTrials.gov (NCT02488759) and is now completed. FINDINGS: Between October, 2015, and March, 2020, 193 patients were recruited in the recurrent or metastatic cervical cancer cohort of CheckMate 358, of whom 176 were treated. 19 patients received nivolumab monotherapy, 45 received NIVO3 plus IPI1, and 112 received NIVO1 plus IPI3 (45 in the randomised group and 67 in the expansion group). Median follow-up times were 19·9 months (IQR 8·2-44·8) with nivolumab, 12·6 months (7·8-37·1) with NIVO3 plus IPI1, and 16·7 months (7·2-27·5) with pooled NIVO1 plus IPI3. Objective response rates were 26% (95% CI 9-51; five of 19 patients) with nivolumab, 31% (18-47; 14 of 45 patients) with NIVO3 plus IPI1, 40% (26-56; 18 of 45 patients) with randomised NIVO1 plus IPI3, and 38% (29-48; 43 of 112 patients) with pooled NIVO1 plus IPI3. The most common grade 3-4 treatment-related adverse events were diarrhoea, hepatic cytolysis, hyponatraemia, pneumonitis, and syncope (one [5%] patient each; nivolumab group), diarrhoea, increased gamma-glutamyl transferase, increased lipase, and vomiting (two [4%] patients each; NIVO3 plus IPI1 group), and increased lipase (nine [8%] patients) and anaemia (seven [6%] patients; pooled NIVO1 plus IPI3 group). Serious treatment-related adverse events were reported in three (16%) patients in the nivolumab group, 12 (27%) patients in the NIVO3 plus IPI1 group, and 47 (42%) patients in the pooled NIVO1 plus IPI3 group. There was one treatment-related death due to immune-mediated colitis in the NIVO1 plus IPI3 group. INTERPRETATION: Nivolumab monotherapy and nivolumab plus ipilimumab combination therapy showed promise in the CheckMate 358 study as potential treatment options for recurrent or metastatic cervical cancer. Future randomised controlled trials of nivolumab plus ipilimumab or other dual immunotherapy regimens are warranted to confirm treatment benefit in this patient population. FUNDING: Bristol Myers Squibb and Ono Pharmaceutical.
引用
- Oaknin A, Moore K, Meyer T, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Lancet Oncol. 2024. PMID: 38608691. doi:10.1016/S1470-2045(24)00088-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。